Past Calls for Proposals
Call For Proposal - A Series (Archive)
Call for Proposals A01 (Hit2Lead)
Call Opens: 20 September 2024
Submission Deadline: 29 October 2024, 1200 hrs (SGT)
Maximum Duration: 12 months
Maximum Quantum: S$2.5 million (including 30% indirect costs)
Scope
Hit2Lead will support RNA drug development from hit generation to lead compound(s) identification.
(This Call is only open to all indications except Infectious Diseases.)
Entry Criteria
Projects applying for Hit2Lead must have a validated target. The application must demonstrate using in vitro and in vivo preclinical models that the target is convincingly implicated in the disease. The application must demonstrate that a tool compound can modulate the target in vitro and in vivo and show improvements in surrogate markers.
Desired Outcomes
At the end of Hit2Lead, projects should identify 3-5 lead compounds that demonstrate efficacy, stability and toxicity in vitro, as well as efficacy in vivo, based on specifications listed in the target product profile.
Call For Proposal - N Series (Archive)
Call for Proposals N07
Call Opens: 20 September 2024
Submission Deadline: 29 October 2024, 1200 hrs (SGT)
Maximum Duration: 36 months
Maximum Quantum: S$5 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Expanding the therapeutic utility of mRNA modalities beyond prophylactic vaccines requires frequent parenteral administration (e.g. intravenous, intramuscular, subcutaneous, intradermal) which leads to non-selective uptake by the liver and results in poor efficacy coupled with dose-limiting toxicities. |
|
Optional
|
RNA: ribonucleic acid; mRNA: messenger RNA
Call for Proposals N06
Call Opens: 20 September 2024
Submission Deadline: 29 October 2024, 1200 hrs (SGT)
Maximum Duration: 36 months
Maximum Quantum: S$5 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Active targeting strategies are needed to achieve organ-/cell-specific, extrahepatic delivery of synthetic RNA, especially ASO and siRNA. |
|
Optional
|
RNA: ribonucleic acid; siRNA: small interfering RNA; ASO: antisense oligonucleotide; IC50: half maximal inhibitory concentration; ED50: median effective dose
Call for Proposals N05
Call Opens: 8 April 2024
Submission Deadline: 31 May 2024, 1200 hrs (SGT)
Maximum Duration: 36 months
Maximum Quantum: S$5 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Current development of safe and effective carriers to encapsulate nucleic acid drugs for various clinical applications is not sufficiently efficient. |
|
Optional
|
Call for Proposals N02
Call Opens: 8 April 2024
Submission Deadline: 31 May 2024, 1200 hrs (SGT)
Maximum Duration: 18 months
Maximum Quantum: S$4 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Current design processes for siRNA and/or ASO drug candidates are not sufficiently holistic to predict downstream effects. |
|
Optional
|
RNA: ribonucleic acid; siRNA: small interfering RNA; ASO: antisense oligonucleotide; IC50: half maximal inhibitory concentration
Call for Proposals N04
Call Opens: 8 April 2024
Submission Deadline: 17 May 2024, 1200 hrs (SGT)
Maximum Duration: 24 months
Maximum Quantum: S$3 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Current designs for mRNA drug candidates are not sufficiently effective. |
|
Optional
|
RNA: ribonucleic acid; mRNA: messenger RNA
Call for Proposals N03
Call Opens: 8 April 2024
Submission Deadline: 17 May 2024, 1200 hrs (SGT)
Maximum Duration: 18 months
Maximum Quantum: S$3 million (including 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. |
Limited access to bespoke chemistries and modifications impedes synthesis of hit compound libraries for siRNA/ASO drug development. |
|
Optional
|
RNA: ribonucleic acid; siRNA: small interfering RNA; ASO: antisense oligonucleotide
Call for Proposals N01
Call Opens: 19 December 2023
Submission Deadline: 24 January 2024, 1200 hrs (SGT)
Maximum Duration: 3 years
Maximum Quantum: S$3 million (excluding 30% indirect costs)
# | Problem Statement | Objectives | Deliverables |
---|---|---|---|
1. | Lack of local production capacities and automation capabilities to accelerate the development of mRNA assets to clinical readiness |
|
|
2. | Lack of local production capacities and automation capabilities to accelerate the development of siRNA/ ASO assets to clinical readiness |
|
|
RNA: ribonucleic acid; mRNA: messenger RNA; siRNA: small interfering RNA; ASO: antisense oligonucleotide; GLP: Good Laboratory Practice; GMP: Good Manufacturing Practice; QbD: Quality by Design
A*STAR celebrates International Women's Day

From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM